The GlaxoSmithKline-sponsored study found that deaths from cervical cancer would drop by 76% with 100% coverage. Cases of cancers in the vulva and vagina could also be reduced from the implementation of the vaccine.
The results were based on the theory that the vaccine would target 12-year-old girls, specifically before they became sexually active. However, they would still continue to receive cervical screenings throughout their life.
GlaxoSmithKline is competing with Merck & Co. which has manufactured a rival vaccine, Gardasil. Gardasil is set to receive a European license and already has received approval from the FDA. Cevarix is still being developed and therefore will not be sent for European approval until next year.